Moneycontrol
you are here: HomeNewsBusiness
Last Updated : Dec 07, 2018 11:09 AM IST | Source: PTI

AstraZeneca Pharma inks distribution pact with Abbott for diabetes drug

Dapagliflozin, an innovative Type 2 diabetes medicine, is AstraZeneca Pharma's leading diabetes medicine.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm AstraZeneca Pharma India on December 7 said it has entered into a distribution agreement with Abbott Healthcare for distribution of diabetes medicine Dapagliflozin in India. Dapagliflozin, an innovative Type 2 diabetes medicine, is AstraZeneca Pharma's leading diabetes medicine.

"Under the agreement, Abbott will promote and distribute Dapagliflozin under the brand name GLEDEPA. Abbott will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name GLEDEPA MET," AstraZeneca Pharma said in a regulatory filing.

AstraZeneca Pharma, which did not share financial details of the agreement, said it will continue to promote and distribute dapagliflozin under the brand name Forxiga and combination of dapagliflozin with metformin under the brand name Xigduo.

Shares of AstraZeneca Pharma were trading 0.54 percent higher at Rs 1,341.35 apiece on BSE.
First Published on Dec 7, 2018 11:08 am
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant